Researchers at the University of Maryland at Baltimore succeeded in delivering nanoparticles into cancer cells that changed packaged DNA into circular DNA, a breakthrough that may have applications for oncology and gene-based therapy.
Drug delivery specialist Genisphere announced that it has raised $2 million in private funding to advance its 3DNA nanotechnology platform through collaborations with pharma companies. The funders are existing investors including Corporate Fuel Partners.
While test strips and expensive polymerase chain reaction (PCR) machines exist in the Ebola detection market, scientists are after a medical device that can detect and prevent the spread of Ebola at a low cost.
Johns Hopkins researchers published a study showing they can use biodegradable nanoparticles to carry DNA to brain cancer cells. The animal study suggests that these vehicles could deliver what they call "death genes" to the cells, treating the cancer while preserving healthy brain cells in the process.
In the 13 years since the publication of the rough draft of the human genetic code, scientists have run thousands of genome-wide association studies to find links between DNA and disease. The work has delivered some insights, but also shown the method has limitations. Now, a new approach could avoid these flaws.
The rise of three-dimensional modeling software has changed how Hollywood studios make movies, architects plan skyscrapers and sportswear companies design running shoes. Now, the same software and design principles are changing how researchers develop drug delivery vehicles.
Exact Sciences stock plunged more than 20% late Thursday morning based on what was ostensibly positive early news about a massive pivotal study for the company's colorectal cancer molecular diagnostic test. While the data met all endpoints, investors clearly wanted better and they punished the company as a result.
Technology behind DVD players (does anyone use those any more?) is gaining a second life as the basis for an inexpensive HIV diagnostic test.
Work is under way on a diagnostic test that would determine the response of a patient with advanced breast cancer to drug treatment, by measuring the DNA that breaks off from dying tumor cells into the bloodstream.
Researchers at the U.K.'s University of Cambridge are developing a way to alter DNA in such a way that would allow certain drugs to pass through cell membranes without a hitch.